JHC – UBS rates the stock as Neutral
In the short-term, UBS expects Japara Healthcare to benefit from the temporary funding in the second half and the increase in indexation in FY22 to 2-3%. Neutral rating maintained with the target price rising to $0.75 from $0.50.
Read More